Advertisement

Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Organisation › Details

Hemab ApS

Hemab is a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in the US and Denmark, Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. The company's strategic guidance, Hemab 1-2-5TM, targets the development of 5 clinical assets by 2025 to deliver long-awaited innovation for patients with Factor VII Deficiency, Bernard Soulier Syndrome, Von Willebrand Disease, Hereditary Hemorrhagic Telangiectasia (or Osler-Weber-Rendu disease), Congenital Antithrombin III Deficiency, and other serious disorders. *

 

Period Start 2019-01-01 established (s-off)
Product Industry therapeutic antibody
Persons Person Faber, Johan H. (Hemab 202012 CEO + Co-Founder)
  Person 2 Petersen, Jørgen Søberg (Novo Group 201907 Venture Partner at Novo Ventures)
     
Region Region København (Copenhagen)
  Country Denmark
  Street 3 Ole Maaløes Vej
  City 2200 København
    Address record changed: 2023-02-22
     
Basic data Employees n. a.
     
    * Document for »About Section«: Hemab ApS. (2/21/23). "Press Release: Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders". Copenhagen & Boston, MA.
     
   
Record changed: 2023-02-22

Advertisement

Picture EBD Group BIO-Europe 2023 Munich BEU23 650x200px

More documents for Hemab ApS


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EasyFairs Connect in Pharma 2023 Geneva Agenda 650x300px




» top